Vcanbio Cell & Gene Engineering Corp Capital Expenditures
The Capital Expenditures (CapEx) of Vcanbio Cell & Gene Engineering Corp (600645.SS) as of Oct 13, 2026 is -49.56 M CNY. In the previous year, Capital Expenditures (CapEx) was -67.32 M CNY — a change of -26.38% (higher).
Get this data via API
Financial Data API
Capital Expenditures
-49.56 MCNY
YoY
-26.38%
Last updated:
The Vcanbio Cell & Gene Engineering Corp Capital Expenditures history
3 Years
10 Years
25 Years
Max
| YEAR | Capital Expenditures | YoY |
|---|---|---|
| -49.56 MCNY | -26.38% | |
| -67.32 MCNY | -24.03% | |
| -88.61 MCNY | -10.66% | |
| -99.19 MCNY | -22.35% | |
| -127.74 MCNY | +39.27% | |
| -91.72 MCNY | -25.40% | |
| -122.95 MCNY | -4.04% | |
| -128.13 MCNY | +54.35% | |
| -83.02 MCNY | -69.24% | |
| -269.85 MCNY | +109.67% | |
| -128.70 MCNY | +112.83% | |
| -60.47 MCNY | — |
Vcanbio Cell & Gene Engineering Corp Stock analysis
Frequently Asked Questions about Vcanbio Cell & Gene Engineering Corp stock
Capital Expenditures (CapEx) of Vcanbio Cell & Gene Engineering Corp is -49.56 M CNY in 2025.
Capital Expenditures (CapEx) of Vcanbio Cell & Gene Engineering Corp changed from -67.32 M CNY to -49.56 M CNY, representing a -26.38% change. The value is higher than the previous year.
On Eulerpool you can find the complete historical development of Capital Expenditures (CapEx) Vcanbio Cell & Gene Engineering Corp since 2006 – with annual values, charts, and detailed analysis.
Capital expenditures represent investments in long-term assets such as property, equipment, and technology. CapEx is essential for maintaining and growing the business.
Capital Expenditures (CapEx)'s CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Capital Expenditures (CapEx)'s Vcanbio Cell & Gene Engineering Corp historically and in real time.
Cash Flow — Vcanbio Cell & Gene Engineering Corp
All Key Metrics — Vcanbio Cell & Gene Engineering Corp
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth